Jim has over 30 years of experience providing products and services to help families and doctors better diagnose and manage health conditions.

Jim was the Chief Business Officer of Integrated Diagnostics, a diagnostics company developing technology for early detection, prediction and prevention of disease. Prior to that he was Senior Vice President of Global Sales and Senior Director of Corporate Development for UnitedHealth Group, Director of Marketing & Corporate Development at Elan Diagnostics and Sales Manager at DIANON Systems.

Jim received the Meritorious Service Medal among other honors while serving as Captain in the United States Army where he was Air-Cavalry Troop Commander, Aviation Task Force Operations Officer, Attack and Scout Helicopter Pilot, among other roles and distinctions.

Jim lives in Florida with his family where he enjoys surfing, golfing and tennis with his wife and two sons.

30 years of human resources and organizational development experience in multiple industries and organization sizes, with the last 10 years in the biotech/life sciences start-up space.

An accomplished data scientist, Heather brings over 20 years of experience in data analysis, software development and data curation.

Dr. R. Sharon Chinthrajah is an Associate Professor at Stanford University, subspecialized in Pulmonary/Critical Care and Allergy/Immunology. She directs the Clinical Translational Research Unit of the Sean N Parker Center for Allergy and Asthma Research where she conducts translational research investigating immune mechanisms in food allergy and asthma and leads the team to conduct novel and impactful Phase 1-4 studies in food allergy, asthma, allergic rhinitis, and atopic dermatitis. She oversees over 26 active clinical trials in the overlapping diseases of food allergy, asthma, allergic rhinitis, eczema, and eosinophilic esophagitis. Dr. Chinthrajah received her MD from Drexel University College of Medicine, completed her Internal Medicine training and a chief residency at California Pacific Medical Center, and subspecialized in Pulmonary/Critical Care and Allergy/Immunology at Boston Medical Center. Her long-term research focus is to advance our understanding of immune dysfunction and regulation in allergic disorders and to apply these insights to develop novel therapeutics to treat these diseases.

Allergy mom of four. Innovative and successful leader with over 15 years of diagnostics, products, and services experience. She has led multiple start-ups to build out their commercial strategy and launch over 25 diagnostic products, including a direct-to-consumer genetics test.

More than 30 years experience with medical device and diagnostics manufacturing, quality assurance and clinical affairs. Extensive experience with FDA and international regulatory body inspections and responses. Senior leadership positions for the development and management of compliant quality systems for large and small device, diagnostics and pharmaceutical companies.

Dr. Gerson is Certified in Anatomic & Clinical Pathology, and Toxicology, having trained at Johns Hopkins University School of Medicine. After being on the faculty of Harvard Medical School, activities include having been Professor of Pathology and of Pharmacology and Clinical Professor of Occupational Medicine at Boston University School of Medicine; Presently he is with the Department of Pathology and Cellular Biology, Jefferson Medical College. Other past activities include Chairperson, Clinical Devices Panel, FDA. Dr. Gerson has served on Boards of Directors and/or Scientific Advisory Boards of various companies. Dr. Gerson has 47 peer reviewed publications, 18 Review publications, 30 Abstracts and Presentations, 2 Books, 6 Book Chapters, Editor of 4 Monographs.

Dr. Getts has over 25 years of biotech research and development experience. The majority of this experience has been focused on the development of biological assays, and reagents to improve life science and diagnostic detection of disease markers as well as improve the delivery of therapeutic molecules. Bob has:

Over 35 peer-review publications, abstracts, and presentations.

More than 20 issued patents and more than 35 submitted patent applications under review,

Over 20 years’ experience in data science, bioinformatics, and software design for medical devices. Developer of multiple clinical CLIA regulated diagnostic tests and FDA regulated medical devices.

Over 20 years of experience in biomarker discovery, diagnostic research and development, and laboratory operations and leadership. Has played a pivotal role in the development and commercialization of numerous high complexity molecular diagnostics.

Jane is an American Society for Clinical Pathology board certified Clinical Laboratory Scientist. She brings 20+ years of high-volume laboratory testing experience.

Her detailed oriented nature is an asset to the company.

Paul is an accomplished scientific leader having invented, developed and commercialized several diagnostic tests. Most recently he has advised Sera Prognostics on the development and launch of their PreTRM product. Paul oversees the evidence development strategy for Sera Prognostics.

Demonstrated laboratory leader with over a decade in the clinical laboratory field. David leads the organization’s staff in a CLIA clinical reference laboratory. He has developed and implemented laboratory processes leading to the discovery, validation, and commercialization of complex precision diagnostic products currently in use. David serves as AACC (American Association for Clinical Chemistry) Industry Division Chairperson.

Digital health entrepreneur and food allergy expert with over 15 years experience capturing the voice of the patient. Erin has advised pharmaceutical companies, tech start-ups, media outlets, government organizations and others on the impact of food allergies.

Per brings 35 years of highly relevant scientific expertise and experience in the development of food allergy diagnostics to Allergenis having serves as Chief Technology Officer of Phadia and later ThermoFisher ImmunoDiagnostics. Per’s domain experience is indusive of business development, Intellectual Property, and research and development strategy.

Per and Hugh Sampson have collaborate for more than 20 years in the development of epitope mapping and other novel advances in the field.

Ashish Patel is a graduate of Loma Linda University's Clinical Laboratory Science program and holds a Master's in Business Administration with a focus in Finance.

As an award-winning industry leader with over 18 years of Regulatory and Transfusion Medicine expertise, he has presented at various conferences, launched new laboratories, and continues to serve as a consultant for laboratory information systems. He is well versed in CAP, Joint Commission, DNV, FDA, CLIA, COLA and ISO standards.

25 years of life science industry experience leading companies from formation through strategic exit. Michael brings recent Dx experience in the field of development disorders having built commercial teams with a dual marketing focus on both physicians and consumers.

Bill Pignato is the Founder and Principal of W.J. Pignato & Associates, LLC a Boston based consulting firm specializing in global regulatory affairs strategy, which is focused on in vitro diagnostics, medical devices, companion diagnostics and precision medicine, drug/diagnostics co-development and the regulatory deployment of new technologies. Previously, Bill was the Vice President, Global Head of Regulatory Affairs, Companion Diagnostics at Novartis where he led the companion diagnostic regulatory program in support of the company’s novel therapeutics in oncology and general medicine. He previously worked at Genentech, Inc leading the regulatory effort specific to the company’s companion diagnostic initiatives. Bill brings 35 years of strategic global diagnostic regulatory affairs experience in support of bringing products to market, including working on more than 60 drug/companion diagnostic co-development programs. Prior positions include Vice President of Regulatory Affairs for EXACT Sciences Corp., an applied genomics company focused on the early detection of colorectal cancer and Vice President of Regulatory Affairs for Valeo Medical. He has also previously held senior regulatory positions at Bayer Diagnostics, Chiron Diagnostics and Ciba-Corning Diagnostics. Bill has been active in numerous FDA/Industry cooperative activities regarding regulatory policy impacting diagnostic devices. He has spoken widely on a number of regulatory issues and challenges associated with commercialization of in vitro diagnostic technologies, including personalized medicine, companion diagnostics and drug/diagnostic co-development.

Over thirty years experience in senior information technology roles including laboratory information management systems.

Thomas is an accomplished Sales and Marketing Leader in the Pharmaceutical and Biotechnology Industry with domain expertise in Precision Medicine and Companion Diagnostics. Through positions at Pfizer, ViiV Healthcare, GSK and AstraZeneca, Thomas gained extensive US & Global companion diagnostic commercial launch experience in the therapeutic areas of HIV and Oncology.

Cindy has over fifteen years of expertise in all areas of business and sales operations including financial modeling, financial planning, sales force design, sales target setting, measurement, forecasting, and sales incentive compensation plan design.

Albert Luderer has over four decades of successful experience in biotechnology, with special focuses on technology, business development and the commercialization of multiple tools and services currently in clinical use.

Dr. Luderer is CEO and board director of molecular therapeutics and imaging company Indi Molecular. He is also a board director of publicly traded Binano Genomics, a genome analysis company providing diagnostic tools and services.

Dr. Luderer previously served as CEO and board director of personalized diagnostics company Integrated Diagnostics, acquired by Biodesix which leveraged the Nodify Lung asset to a successful IPO. Prior to his role with Indi, Dr. Luderer was president and CEO of BioTrove, a venture-backed molecular biological tools company acquired by Life Technologies.

Additionally, Dr. Luderer was CEO of venture-backed therapeutics company Light Sciences and president and COO of bioMérieux, Inc. He held senior management positions at DIANON Systems (LabCorp), Boehringer Mannheim (Roche), and Ciba-Corning rounding out Dr. Luderer’s experience in the industry.

He earned his PhD from Rutgers University, where he was a National Science Foundation predoctoral fellow, and performed postgraduate work in immunology at Jefferson Medical College.

Vijay has over thirty years of experience in both pharmaceutical services and clinical diagnostics. He is currently a Partner of The Channel Group, LLC and its affiliate, BioMed Transition Partners, a New York-based life sciences venture development and management firm, engaging in venture formation and transactions.

Most recently, Dr. Aggarwal was President and CEO of Aureon Laboratories, Inc., a predictive pathology company offering advanced tissue analysis services to practicing physicians and the pharmaceutical industry. Previously, Dr. Aggarwal was President of Quest Diagnostic Ventures, where he had responsibility for new technology, new business models, clinical trials testing, and direct-to-consumer strategies.

Earlier in his career, Dr. Aggarwal held many positions with SmithKline Beecham Clinical Laboratories, including direct responsibility for all of SBCL’s U.S.-based laboratories as Executive Vice President of Laboratories, Vice President of Managed Care. He earned a BA in Chemistry from Case Western Reserve University and a Ph.D. in Pharmacology/Toxicology from the Medical College of Virginia.

David Esposito is President and CEO of ONL Therapeutics, a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions. As an experienced healthcare executive, David has built and scaled multiple companies that resulted in successful exits to strategic buyers.

David is the former CEO of Armune BioScience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer. The Company successfully launched the only non-PSA blood test to improve the detection of prostate cancer. Armune BioScience was sold to Exact Sciences (EXAS) in 2017.

He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) for in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing and commercial strategy for the US Division.

David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.

Russ Fein began his career in 1987 in the Mergers and Acquisitions department of Jefferies & Company, Inc. where he worked on numerous complex transactions. He then spent a number of years in the merchant banking field where he negotiated acquisitions and investments both as principal and agent and often stepped in as COO and/or CFO of portfolio companies, leading growth strategies and building professional organizations around entrepreneurial businesses.

In 1995, he left the investment banking field to work full time in senior management roles at a number of small and large operating businesses, including a chain of martial art studios, an Internet incubator and most recently as the Vice President, Worldwide Business Operations for Westcon Group, a $4 billion distributor of communications and technology equipment, where he also held the role of General Manager for a $300mm U.S. division.

Russ received his MBA from the University of Chicago Graduate School of Business and graduated from Union College with honors in Managerial Economics.

Jim has over 30 years of experience providing products and services to help families and doctors better diagnose and manage health conditions.

Jim was the Chief Business Officer of Integrated Diagnostics, a diagnostics company developing technology for early detection, prediction and prevention of disease. Prior to that he was Senior Vice President of Global Sales and Senior Director of Corporate Development for UnitedHealth Group, Director of Marketing & Corporate Development at Elan Diagnostics and Sales Manager at DIANON Systems.

Jim received the Meritorious Service Medal among other honors while serving as Captain in the United States Army where he was Air-Cavalry Troop Commander, Aviation Task Force Operations Officer, and Helicopter Attack Pilot, among other roles and distinctions.

Jim lives in Florida with his family where he enjoys surfing, golfing and tennis with his wife and two sons.

John Simons has spent 33 years as a banker and advisor to small and mid-size businesses and the families that own them. John was formerly an Executive Vice President for Bank of America (formerly Fleet National Bank) in the Regional Commercial Services Group, responsible for small business, middle market and corporate banking in New York City, Long Island, New Jersey and the Hudson Valley area. He was also Market Executive for FleetBoston Financial’s activities in New York City. Prior to joining Fleet, John was a Senior Vice President with Chase Manhattan Bank. He began his career with Chemical Bank in 1983.

John is a Director of The United Hospital Fund, a Trustee of amfAR, The American Foundation for Aids Research, and a former Trustee of the Brooklyn Academy of Music. John was also Chairman of the Lincoln Center Business Council and a member of Lincoln Center Corporate Fund. John was appointed by Mayor Bloomberg in 2003 to be a member of the Mayor’s Fund to Advance New York City. John has a bachelor’s degree from Trinity College.